Evidence map›Paper›PMID 34406502›Full record

Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2022

Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.

M Filippelli, R dell'Omo, A Gelso, M Rinaldi, S Bartollino, P Napolitano, A Russo, G Campagna, C Costagliola

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04536129 (Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure in Patients With and Without Glaucoma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04536129 nacompletednot on this map

Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure in Patients With and Without Glaucoma

TypeinterventionalSponsorUniversity of MoliseRan2019 to 2020Enrolled90ConditionsOcular Surface Disease, GlaucomaArmsHydrocortisone (CORTIVIS ®)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

M FilippelliDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy. oftelena@gmail.com.ORCID http://orcid.org/0000-0003-1950-0200
R dell'OmoDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.ORCID http://orcid.org/0000-0002-7663-8874
A Gelso"Villa Dei Fiori" Hospital, Acerra, Naples, Italy.
M RinaldiDepartment of Ophthalmology, University Della Campania Luigi Vanvitelli, Naples, Italy.
S BartollinoDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
P NapolitanoDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.ORCID http://orcid.org/0000-0001-6044-7486
A Russo"Villa Dei Fiori" Hospital, Acerra, Naples, Italy.
G CampagnaDepartment of Medical-Surgical Sciences and Translational Medicine, University of Rome "La Sapienza", Rome, Italy.ORCID http://orcid.org/0000-0002-1884-9171
C CostagliolaDepartment of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.ORCID http://orcid.org/0000-0001-8477-6188
University of Molise · ITSapienza University of Rome · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to investigate the safety and efficacy of short-term treatment for ocular surface disease (OSD) with topical low-dose (1,005 mg) preservative-free hydrocortisone in one hundred patients with and without glaucoma.

methodsThis was an open label non-randomized clinical trial. Patients with OSD with and without primary open-angle glaucoma (POAG) received topical low-dose (1,005 mg) preservative-free hydrocortisone twice daily in each eye for 2 weeks. All patients underwent a complete ophthalmological examination at baseline (T0) and at 1 (T1) and 2 (T2) weeks post-treatment. At each visit, the intraocular pressure (IOP) and the ocular surface disease index (OSDI) questionnaire scores were recorded; the Schirmer test was performed only at T0 and T2.

resultsThe OSDI score significantly decreased in both the POAG and no-POAG groups (both p < 0.0001) after hydrocortisone treatment, with no difference between the two groups (p = 0.72). There were no significant differences in IOP and Schirmer test results between T0 and T2 in both treatment groups (p = 0.68 and p = 0.83, respectively).

conclusionsTopical low-dose (1,005 mg) preservative-free hydrocortisone is safe and effective for improving OSD symptoms both in patients with and without POAG.

trial registrationThe trial was registered at clinicaltrials.gov under NCT04536129 on 01/09/2020 ("retrospectively registered").

Indexed as

GlaucomaGlaucoma, Open-AngleOcular HypertensionAntihypertensive AgentsHumansHydrocortisoneIntraocular PressureOphthalmic SolutionsPreservatives, PharmaceuticalAntihypertensive AgentsHydrocortisoneOphthalmic SolutionsPreservatives, PharmaceuticalIntraocular pressureOcular surface diseaseOpen-angle glaucomaTopical hydrocortisone

Identifiers

PMID34406502
OpenAlexW3196251037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.